Details of the Drug Combination

General Information of Drug Combination (ID: DCUH8YL)

• Drug Combination Name: Bendamustine hydrochloride + ER819762
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Bendamustine hydrochloride (DMFH15Z): Small molecular drug: 3D MOL is unavailable
  ER819762 (DMSG91J): Small molecular drug: 3D MOL is unavailable
• High-throughput Screening Result:
  Testing Cell Line: K-562
  Zero Interaction Potency (ZIP) Score: 14.51
  Bliss Independence Score: 16.8
  Loewe Additivity Score: 12.28
  LHighest Single Agent (HSA) Score: 12.73

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Bendamustine hydrochloride

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Approved	[2]

Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[2]

Bendamustine hydrochloride Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[5]

Bendamustine hydrochloride Interacts with 13 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[4]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[4]
Beta-galactosidase (GLB1)	OTB0TKAG	BGAL_HUMAN	Increases Expression	[6]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[4]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Increases Activity	[4]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[4]
Caspase-6 (CASP6)	OTXLD3EC	CASP6_HUMAN	Increases Activity	[4]
Baculoviral IAP repeat-containing protein 3 (BIRC3)	OT3E95KB	BIRC3_HUMAN	Decreases Expression	[4]
Baculoviral IAP repeat-containing protein 2 (BIRC2)	OTFXFREP	BIRC2_HUMAN	Decreases Expression	[7]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[4]
PRKC apoptosis WT1 regulator protein (PAWR)	OTKY7W52	PAWR_HUMAN	Decreases Expression	[4]
Diablo IAP-binding mitochondrial protein (DIABLO)	OTHJ9MCZ	DBLOH_HUMAN	Increases Localization	[4]
Death domain-associated protein 6 (DAXX)	OTX6O7PL	DAXX_HUMAN	Decreases Expression	[4]

Indication(s) of ER819762

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

ER819762 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Antagonist	[8]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adult T acute lymphoblastic leukemia	DCN133M	MOLT-4	Investigative	[1]
Astrocytoma	DC1RSOU	U251	Investigative	[1]
Astrocytoma	DC4R46M	SNB-19	Investigative	[1]
Renal cell carcinoma	DCOUJG7	SN12C	Investigative	[1]
Renal cell carcinoma	DCEHLPP	UO-31	Investigative	[1]
Colon adenocarcinoma	DCD4Z31	COLO 205	Investigative	[9]
Invasive ductal carcinoma	DCVJ3CY	T-47D	Investigative	[9]
Adenocarcinoma	DCZDC18	DU-145	Investigative	[10]
Adenocarcinoma	DCYTVNO	OVCAR3	Investigative	[10]
Adenocarcinoma	DCOIPV3	A549	Investigative	[10]
Adenocarcinoma	DC4X1OX	HCT-15	Investigative	[10]
Adenocarcinoma	DC9C10M	SW-620	Investigative	[10]
Adenocarcinoma	DCP3B3J	HCT116	Investigative	[10]
Cutaneous melanoma	DCIZ3VS	SK-MEL-5	Investigative	[10]
High grade ovarian serous adenocarcinoma	DCT7AA4	OVCAR-5	Investigative	[10]
Large cell lung carcinoma	DCTRK6S	NCI-H460	Investigative	[10]
Lung adenocarcinoma	DCKDSZ9	HOP-62	Investigative	[10]
Lung adenocarcinoma	DCE2HNU	NCI-H522	Investigative	[10]
Malignant melanoma	DCGEBSR	UACC62	Investigative	[10]
Melanoma	DC5IV2K	SK-MEL-2	Investigative	[10]
Mixed endometrioid and clear cell carcinoma	DCFYZAL	IGROV1	Investigative	[10]
Prostate carcinoma	DCWI0RX	PC-3	Investigative	[10]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4040).
• [4] Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
• [5] Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
• [6] Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
• [7] Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
• [8] A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310.
• [9] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [10] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.